BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38377381)

  • 1. Hemangioma of the Ilium Simulating Bone Metastasis on 18 F-PSMA-1007 PET/CT.
    Dong A; Nian S; Bai Y; Zuo C
    Clin Nucl Med; 2024 Jun; 49(6):e304-e306. PubMed ID: 38377381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intense 18 F-PSMA-1007 Uptake of Splenic Hemangioma.
    Jia G; Dong A; Cheng C; Zuo C
    Clin Nucl Med; 2024 Feb; 49(2):e90-e92. PubMed ID: 38048527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. False-Positive 18F-PSMA-1007 and True-Negative 18F-Fluorocholine PET/CT Splenic Hemangioma.
    Panagiotidis E; Paschali A; Xourgia X; Chatzipavlidou V
    Clin Nucl Med; 2020 Dec; 45(12):960-961. PubMed ID: 33065626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rib Fractures Mimicking Bone Metastases in 18F-PSMA-1007 PET/CT for Prostate Cancer.
    Panagiotidis E; Paschali A; Giannoula E; Chatzipavlidou V
    Clin Nucl Med; 2019 Jan; 44(1):e46-e48. PubMed ID: 30371591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vertebral Hemangioma Mimicking Bone Metastasis in 68Ga-PSMA Ligand PET/CT.
    Artigas C; Otte FX; Lemort M; van Velthoven R; Flamen P
    Clin Nucl Med; 2017 May; 42(5):368-370. PubMed ID: 28319497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-Specific Membrane Antigen PET/CT Findings for Hepatic Hemangioma.
    Bhardwaj H; Stephens M; Bhatt M; Thomas PA
    Clin Nucl Med; 2016 Dec; 41(12):968-969. PubMed ID: 27749413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical insignificance of [
    Arnfield EG; Thomas PA; Roberts MJ; Pelecanos AM; Ramsay SC; Lin CY; Latter MJ; Garcia PL; Pattison DA
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4495-4507. PubMed ID: 34136957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-Head Comparison of
    Kuten J; Fahoum I; Savin Z; Shamni O; Gitstein G; Hershkovitz D; Mabjeesh NJ; Yossepowitch O; Mishani E; Even-Sapir E
    J Nucl Med; 2020 Apr; 61(4):527-532. PubMed ID: 31562225
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate-Specific Membrane Antigen-Avid Neurofibroma Mimicking Cutaneous Metastasis in Metastatic Castration-Resistant Prostate Cancer on 18 F-PSMA-1007 PET/CT.
    Aggarwal P; Ambalavanan N; Sood A; Gupta K; Dahiya D; Mittal BR
    Clin Nucl Med; 2024 Jun; 49(6):e286-e287. PubMed ID: 38598513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of [
    Mingels C; Bohn KP; Rominger A; Afshar-Oromieh A; Alberts I
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2436-2444. PubMed ID: 35067735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective comparison of
    Malaspina S; Anttinen M; Taimen P; Jambor I; Sandell M; Rinta-Kiikka I; Kajander S; Schildt J; Saukko E; Noponen T; Saunavaara J; Dean PB; Sequeiros RB; Aronen HJ; Kemppainen J; Seppänen M; Boström PJ; Ettala O
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2951-2959. PubMed ID: 33715033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of malignancy and PSMA expression of uncertain bone foci in [
    Vollnberg B; Alberts I; Genitsch V; Rominger A; Afshar-Oromieh A
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3910-3916. PubMed ID: 35482114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls.
    Keidar Z; Gill R; Goshen E; Israel O; Davidson T; Morgulis M; Pirmisashvili N; Ben-Haim S
    Cancer Imaging; 2018 Nov; 18(1):39. PubMed ID: 30382889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient.
    Marafi F; Sasikumar A; Aldaas M; Esmail A
    Clin Nucl Med; 2021 Jan; 46(1):e65-e67. PubMed ID: 33181733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
    Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
    Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Predicting Metastatic Disease in
    Chiu LW; Lawhn-Heath C; Behr SC; Juarez R; Perez PM; Lobach I; Bucknor MD; Hope TA; Flavell RR
    J Nucl Med; 2020 Dec; 61(12):1779-1785. PubMed ID: 32303599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging
    Chen MY; Franklin A; Yaxley J; Gianduzzo T; McBean R; Wong D; Tatkovic A; McEwan L; Walters J; Kua B
    BJU Int; 2020 Sep; 126(3):396-401. PubMed ID: 32592330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.